Search

Your search keyword '"Marco A. J. Iafolla"' showing total 37 results

Search Constraints

Start Over You searched for: Author "Marco A. J. Iafolla" Remove constraint Author: "Marco A. J. Iafolla"
37 results on '"Marco A. J. Iafolla"'

Search Results

1. Managing Select Immune-Related Adverse Events in Patients Treated with Immune Checkpoint Inhibitors

2. A Guide to Implementing Immune Checkpoint Inhibitors within a Cancer Program: Experience from a Large Canadian Community Centre

3. Point of Care Molecular Testing: Community-Based Rapid Next-Generation Sequencing to Support Cancer Care

4. Clinicopathologic factors that influence prognosis and survival outcomes in men with metastatic castration‐resistant prostate cancer treated with Radium‐223

5. Pan-cancer analysis of longitudinal metastatic tumors reveals genomic alterations and immune landscape dynamics associated with pembrolizumab sensitivity

6. Pan-cancer analysis of longitudinal metastatic tumors reveals genomic alterations and immune landscape dynamics associated with pembrolizumab sensitivity

7. Personalized circulating tumor DNA analysis as a predictive biomarker in solid tumor patients treated with pembrolizumab

8. Real-World Assessment of Clinical Outcomes Among First-Line Sunitinib Patients with Clear Cell Metastatic Renal Cell Carcinoma (mRCC) by the International mRCC Database Consortium Risk Group

9. A Guide to Implementing Immune Checkpoint Inhibitors within a Cancer Program: Experience from a Large Canadian Community Centre

10. Evaluation of liver enzyme elevations and hepatotoxicity in patients treated with checkpoint inhibitor immunotherapy

11. Outcomes of Patients with Metastatic Renal Cell Carcinoma Treated with Targeted Therapy After Immuno-oncology Checkpoint Inhibitors

12. Predicting Toxicity and Response to Pembrolizumab Through Germline Genomic HLA Class 1 Analysis

13. Systematic Review and STARD Scoring of Renal Cell Carcinoma Circulating Diagnostic Biomarker Manuscripts

14. Personalized circulating tumor DNA analysis as a predictive biomarker in solid tumor patients treated with pembrolizumab

16. 668P Clinical factors that are prognostic for survival outcomes in men with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223

17. First-line Immuno-Oncology Combination Therapies in Metastatic Renal-cell Carcinoma: Results from the International Metastatic Renal-cell Carcinoma Database Consortium

18. Serum PD-1 Is Elevated after Pembrolizumab Treatment but Has No Predictive Value

19. Systematic review and REMARK scoring of renal cell carcinoma prognostic circulating biomarker manuscripts

20. Abstract CT301: A phase Ib study to evaluate RO7198457, an individualized Neoantigen Specific immunoTherapy (iNeST), in combination with atezolizumab in patients with locally advanced or metastatic solid tumors

21. Impact of an immuno-oncology (IO) education/monitoring program on patient’s self-efficacy and adverse event reporting from immune checkpoint inhibitors (ICIs)

22. Results of a first-in-human phase I study of SRF231, a fully human, high-affinity anti-CD47 antibody

23. Abstract PR03: Immuno-mass spectrometric identification of serum biomarkers of response and toxicity to pembrolizumab

24. Prognostic factors that affect survival outcomes in men with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223

25. Rational design and identification of immuno-oncology drug combinations

26. Bespoke circulating tumor DNA (ctDNA) analysis as a predictive biomarker in solid tumor patients (pts) treated with single agent pembrolizumab (P)

27. Bespoke circulating tumor DNA (ctDNA) analysis as a predictive biomarker in solid tumor patients (pts) treated with single-agent pembrolizumab (P)

28. PS-139-Liver enzyme elevations and hepatotoxicity in patients treated with checkpoint inhibitor immunotherapy

29. Real-world assessment of clinical outcomes among first-line (1L) sunitinib (SUN) patients (pts) with metastatic renal cell carcinoma (mRCC) by the international mRCC database consortium (IMDC) risk group

30. Systematic review and REMARK scoring of renal cell carcinoma (RCC) prognostic circulating biomarker manuscripts

31. Patterns of response of organ specific metastasis in patients with metastatic renal cell cancer (mRCC) treated with an immune checkpoint inhibitor (CPI) post tyrosine kinase inhibitor (TKI)

32. Predicting toxicity and response to pembrolizumab (P) through germline genomic HLA class I analysis

33. Dark proteins: Effect of inclusion body formation on quantification of protein expression

34. Simplification of Stochastic Chemical Reaction Models with Fast and Slow Dynamics

35. Increasing the efficiency of bacterial transcription simulations: When to exclude the genome without loss of accuracy

36. Extracting biochemical parameters for cellular modeling: A mean-field approach

37. Systematic review and REMARK scoring of renal cell carcinoma prognostic circulating biomarker manuscripts.

Catalog

Books, media, physical & digital resources